Systemic role for vitamin d in the treatment of psoriasis and metabolic syndrome

Lisa Wenyang Fu, Ronald Vender, Lisa Wenyang Fu, Ronald Vender

Abstract

The novel discovery of the systemic role of vitamin D in the modulation of the immune system especially the Type 1 helper T cell (Th1) pathway reveals its potential for treating Th1 inflammatory diseases. Psoriasis has been recently established to be a systemic disease centered on inflammation and involvement of cytokines of the Th1 pathway. There is an increased prevalence of metabolic syndrome in patients with psoriasis. Metabolic syndrome also involves a proinflammatory state. This paper proposes the idea of the potential use of oral vitamin D to treat psoriasis and metabolic syndrome concurrently. We propose there is merit in more clinical trials investigating the use of vitamin D to treat both psoriasis and metabolic syndrome through its anti-inflammatory effects. On application to psoriasis management and prognosis, the goal is to decrease the risk for cardiovascular disease and decrease disease morbidity and mortality.

References

    1. Holick MF. Medical progress: vitamin D deficiency. The New England Journal of Medicine. 2007;357(3):266–281.
    1. Ikeda U, Wakita D, Ohkuri T, et al. 1α,25-dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells. Immunology Letters. 2010;134(1):7–16.
    1. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. American Journal of Clinical Nutritio. 2004;80(supplement):1717S–1720S.
    1. Schön MP, Boehncke WH. Psoriasis. The New England Journal of Medicine. 2005;352(18):1899–1912.
    1. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Annals of the Rheumatic Diseases. 2005;64(supplement 2):ii18–ii23.
    1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271.
    1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428.
    1. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinology and Metabolism Clinics of North America. 2004;33(2):351–375.
    1. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. British Journal of Dermatology. 2007;157(1):68–73.
    1. Peternel S, Kaštelan M. Immunopathogenesis of psoriasis: focus on natural killer T cells. Journal of the European Academy of Dermatology and Venereology. 2009;23(10):1123–1127.
    1. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annual Review of Medicine. 2005;56:45–62.
    1. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. Journal of Dermatological Treatment. 2008;19(1):5–21.
    1. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Archives of Dermatological Research. 2006;298(7):321–328.
    1. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Current Opinion in Rheumatology. 2008;20(4):416–422.
    1. Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis: evidence from the psocare project. Dermatology. 2008;217(4):365–373.
    1. Hossler EW, Maroon MS, Mowad CM. Gastric bypass surgery improves psoriasis. Journal of the American Academy of Dermatology. In press.
    1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874.
    1. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. Journal of the American Medical Association. 2006;296(14):1735–1741.
    1. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Archives of Dermatology. 2007;143(12):1493–1499.
    1. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. European Heart Journal. 2010;31(8):1000–1006.
    1. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. Journal of the American College of Cardiology. 2010;56(14):1113–1132.
    1. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683–689.
    1. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Journal of the American Medical Association. 2002;288(21):2709–2716.
    1. Abramovits W. Calcitriol 3 microg/g ointment: an effective and safe addition to the armamentarium in topical psoriasis therapy. Journal of Drugs in Dermatology. 2009;8(supplement 8):s17–s22.
    1. Van De Kerkhof PCM. The topical treatment of psoriasis. Clinical and Experimental Dermatology. 2005;30(2):205–208.
    1. Tanghetti EA. The role of topical vitamin D modulators in psoriasis therapy. Journal of Drugs in Dermatology. 2009;8(supplement 8):s4–s8.
    1. Lehmann B. Role of the vitamin D pathway in healthy and diseased skin—facts, contradictions and hypotheses. Experimental Dermatology. 2009;18(2):97–108.
    1. Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D) for the treatment of psoriasis. British Journal of Dermatology. 1996;134(6):1070–1078.
    1. Werner de Castro GR, Neves FS, Pereira IA, Fialho SC, Ribeiro G, Zimmermann AF. Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment. Rheumatology International. In press.
    1. Botella-Carretero JI, Alvarez-Blasco F, Villafruela JJ, Balsa JA, Vázquez C, Escobar-Morreale HF. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clinical Nutrition. 2007;26(5):573–580.
    1. Matilainen JM, Husso T, Toropainen S, et al. Primary effect of 1α,25(OH)2D3 on IL-10 expression in monocytes is short-term down-regulation. Biochimica Biophysica Acta. 2010;1803(11):1276–1286.
    1. Tzotzas T, Papadopoulou FG, Tziomalos K, et al. Rising serum 25-hydroxy-vitamin D levels after weight loss in obese women correlate with improvement in insulin resistance. Journal of Clinical Endocrinology and Metabolism. 2010;95(9):4251–4257.
    1. Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. American Journal of Clinical Nutrition. 2004;79(5):820–825.
    1. Alvarez JA, Ashraf A. Role of vitamin d in insulin secretion and insulin sensitivity for glucose homeostasis. International Journal of Endocrinology. 2010;2010 Article ID 351385.
    1. Maki KC, Rubin MR, Wong LG, et al. Serum 25-hydroxyvitamin D is independently associated with high-density lipoprotein cholesterol and the metabolic syndrome in men and women. Journal of Clinical Lipidology. 2009;3(4):289–296.
    1. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. Review: the role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism. 2007;92(6):2017–2029.
    1. McConnell JP, Foley KF, Vargas GM. Hypovitaminosis D: a new risk marker for cardiovascular disease. Clinical Laboratory Science. 2009;22(4):240–246.
    1. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–511.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe